Journal
CELLS
Volume 11, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/cells11091463
Keywords
biliary tract cancer; targeted therapy; DNA damage; synthetic lethality; PARP; Wee1
Categories
Funding
- Italian Foundation of Cancer Research (Fondazione Italiana per la Ricerca sul Cancro
- FIRC) [IG23117]
- AIRC [IG23117]
- COST Association [CA18122]
Ask authors/readers for more resources
Cholangiocarcinoma is a difficult to treat cancer with a rising incidence. Understanding its biology has been a hurdle to identify novel targets and effective treatments. Alterations in DNA damage response-related genes open up possibilities for DDR-targeting strategies. However, using DDR inhibitors alone may not be sufficient for clinical use, leading to consideration of combining them with DNA-damaging regimens and targeted drugs.
Cholangiocarcinoma (CCA) is a poorly treatable type of cancer and its incidence is dramatically increasing. The lack of understanding of the biology of this tumor has slowed down the identification of novel targets and the development of effective treatments. Based on next generation sequencing profiling, alterations in DNA damage response (DDR)-related genes are paving the way for DDR-targeting strategies in CCA. Based on the notion of synthetic lethality, several DDR-inhibitors (DDRi) have been developed with the aim of accumulating enough DNA damage to induce cell death in tumor cells. Observing that DDRi alone could be insufficient for clinical use in CCA patients, the combination of DNA-damaging regimens with targeted approaches has started to be considered, as evidenced by many emerging clinical trials. Hence, novel therapeutic strategies combining DDRi with patient-specific targeted drugs could be the next level for treating cholangiocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available